Magenta Therapeutics Voluntarily Pauses The MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial To Investigate Drug Safety

Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering

Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis

Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock